BRPI1011394A8 - método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40 - Google Patents
método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40 Download PDFInfo
- Publication number
- BRPI1011394A8 BRPI1011394A8 BRPI1011394A BRPI1011394A BRPI1011394A8 BR PI1011394 A8 BRPI1011394 A8 BR PI1011394A8 BR PI1011394 A BRPI1011394 A BR PI1011394A BR PI1011394 A BRPI1011394 A BR PI1011394A BR PI1011394 A8 BRPI1011394 A8 BR PI1011394A8
- Authority
- BR
- Brazil
- Prior art keywords
- linforma
- responsiveness
- assessing
- cell
- antibody treatment
- Prior art date
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title 1
- 230000004043 responsiveness Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17061509P | 2009-04-18 | 2009-04-18 | |
| PCT/US2010/031528 WO2010121231A1 (en) | 2009-04-18 | 2010-04-17 | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1011394A2 BRPI1011394A2 (pt) | 2016-03-15 |
| BRPI1011394A8 true BRPI1011394A8 (pt) | 2018-06-26 |
Family
ID=42358184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011394A BRPI1011394A8 (pt) | 2009-04-18 | 2010-04-17 | método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9617600B2 (enExample) |
| EP (1) | EP2419531B1 (enExample) |
| JP (1) | JP5836929B2 (enExample) |
| KR (1) | KR101787768B1 (enExample) |
| CN (1) | CN102459639A (enExample) |
| AU (1) | AU2010236168B2 (enExample) |
| BR (1) | BRPI1011394A8 (enExample) |
| CA (1) | CA2758523C (enExample) |
| ES (1) | ES2605228T3 (enExample) |
| IL (1) | IL215707A (enExample) |
| MX (1) | MX2011010938A (enExample) |
| WO (1) | WO2010121231A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0820707A2 (pt) | 2007-11-07 | 2015-06-16 | Genentech Inc | Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 |
| CN103635488B (zh) | 2011-04-29 | 2016-12-14 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| ES2634254T3 (es) | 2011-09-12 | 2017-09-27 | Atrys Health, SA | Métodos para el pronóstico del linfoma difuso de linfocitos B grandes |
| HUE049569T2 (hu) | 2012-08-09 | 2020-09-28 | Celgene Corp | Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| EP2914627B1 (en) | 2012-10-30 | 2021-04-07 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| TWI794885B (zh) | 2014-05-19 | 2023-03-01 | 美商西建公司 | 全身紅斑性狼瘡之治療 |
| JP2018529344A (ja) * | 2015-09-25 | 2018-10-11 | セルジーン コーポレイション | びまん性大細胞型ｂ細胞リンパ腫の治療方法及び薬物に対する応答性の予測因子としてのバイオマーカー利用 |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| WO2022120038A1 (en) * | 2020-12-02 | 2022-06-09 | Albert Einstein College Of Medicine | Method for predicting patient response to cd40-targeted therapies |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| DE69433820T2 (de) | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US6248535B1 (en) * | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
| IL151865A0 (en) | 2000-03-31 | 2003-04-10 | Genentech Inc | Compositions and methods for detecting and quantifying gene expression |
| WO2001083755A2 (en) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| WO2002078766A2 (en) | 2001-04-02 | 2002-10-10 | Genentech, Inc. | Combination therapy |
| JP4025881B2 (ja) | 2001-04-27 | 2007-12-26 | キリンファーマ株式会社 | 抗ｃｄ４０モノクローナル抗体 |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| WO2004071572A2 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| US7711492B2 (en) | 2003-09-03 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for diagnosing lymphoma types |
| RS53073B (sr) | 2003-11-04 | 2014-04-30 | Novartis Vaccines And Diagnostics Inc. | Upotreba antagonističkih anti-cd40 monoklonska antitela |
| SI1682177T1 (sl) | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostic | Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije |
| CA2848463A1 (en) * | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| WO2006125143A2 (en) * | 2005-05-18 | 2006-11-23 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| JP5421590B2 (ja) * | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法 |
| ATE485057T1 (de) * | 2005-05-26 | 2010-11-15 | Seattle Genetics Inc | Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung |
| JP5904569B2 (ja) * | 2005-06-08 | 2016-04-13 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 癌治療を受けている患者の同定、判定および処置のための方法 |
| JP2009508484A (ja) * | 2005-09-16 | 2009-03-05 | バイオベイター・テクノロジーズ・アクチボラゲット | アレルゲン性タンパク質の同定のためのインビトロアッセイ |
| DE102005052384B4 (de) * | 2005-10-31 | 2009-09-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens |
| MX2008007140A (es) | 2005-12-09 | 2009-03-04 | Seattle Genetics Inc | Metodos para utilizar agentes de union a cd40. |
| US7527774B2 (en) | 2005-12-22 | 2009-05-05 | Basf Catalysts Llc | Inlet metallic foam support coupled to precious metal catalyst for application on 4 stroke platforms |
| EP1987161A4 (en) * | 2006-01-20 | 2009-06-24 | Univ Mcgill | METHOD FOR IDENTIFYING CD40-SENSITIVE CELLS |
| RU2473555C2 (ru) | 2006-12-19 | 2013-01-27 | ДжинГоу, Инк. | Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных |
| BRPI0820707A2 (pt) * | 2007-11-07 | 2015-06-16 | Genentech Inc | Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 |
-
2010
- 2010-04-17 US US13/264,973 patent/US9617600B2/en active Active
- 2010-04-17 EP EP10715067.4A patent/EP2419531B1/en active Active
- 2010-04-17 BR BRPI1011394A patent/BRPI1011394A8/pt active Search and Examination
- 2010-04-17 KR KR1020117027354A patent/KR101787768B1/ko active Active
- 2010-04-17 JP JP2012505990A patent/JP5836929B2/ja active Active
- 2010-04-17 CA CA2758523A patent/CA2758523C/en active Active
- 2010-04-17 MX MX2011010938A patent/MX2011010938A/es active IP Right Grant
- 2010-04-17 CN CN201080027267XA patent/CN102459639A/zh active Pending
- 2010-04-17 ES ES10715067.4T patent/ES2605228T3/es active Active
- 2010-04-17 AU AU2010236168A patent/AU2010236168B2/en not_active Ceased
- 2010-04-17 WO PCT/US2010/031528 patent/WO2010121231A1/en not_active Ceased
-
2011
- 2011-10-11 IL IL215707A patent/IL215707A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2758523C (en) | 2019-03-12 |
| MX2011010938A (es) | 2012-01-12 |
| JP5836929B2 (ja) | 2015-12-24 |
| US9617600B2 (en) | 2017-04-11 |
| WO2010121231A1 (en) | 2010-10-21 |
| AU2010236168A1 (en) | 2011-11-10 |
| BRPI1011394A2 (pt) | 2016-03-15 |
| IL215707A0 (en) | 2012-01-31 |
| IL215707A (en) | 2016-08-31 |
| US20120123695A1 (en) | 2012-05-17 |
| ES2605228T3 (es) | 2017-03-13 |
| AU2010236168B2 (en) | 2015-08-13 |
| CN102459639A (zh) | 2012-05-16 |
| EP2419531A1 (en) | 2012-02-22 |
| CA2758523A1 (en) | 2010-10-21 |
| KR20120013992A (ko) | 2012-02-15 |
| JP2012523838A (ja) | 2012-10-11 |
| EP2419531B1 (en) | 2016-09-07 |
| KR101787768B1 (ko) | 2017-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011394A8 (pt) | método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40 | |
| BRPI0917145A2 (pt) | Método para fabricar biocombustíveis | |
| BRPI0911077A2 (pt) | método para tratamento de biomassa | |
| BRPI1014262A2 (pt) | anticorpos específicos para caderina-17 | |
| BRPI0916973A2 (pt) | anticorpos para ccr2 | |
| BRPI0921726A2 (pt) | método e dispositivo para ativar células tronco | |
| BRPI1012204A2 (pt) | método de pré-tratamento de biomassa para preparar bioetanol | |
| BRPI0917204A2 (pt) | variantes estruturais de anticorpos para melhores características terapêuticas | |
| PT3425805T (pt) | Codificação de matriz de amostra para baixo atraso | |
| PT2718422T (pt) | Meios de cultura para células estaminais | |
| PL2755389T3 (pl) | Sposób predykcji inter i urządzenie do niego | |
| BR112012004707A2 (pt) | método | |
| BR112012001100A2 (pt) | aparelho e método para construções de estrutura e tijolo | |
| BR112012031294A2 (pt) | um método para transferência quantitativa de analitos | |
| BRPI0908412A2 (pt) | método para purificar álcool de fermentação | |
| BRPI0819050A2 (pt) | Método para desidroaromatizar metano | |
| BRPI1011226A2 (pt) | métodos para tratar condições relacionadas ao cabelo | |
| BRPI0910286A2 (pt) | métodos para transformação de levedura | |
| BRPI0922490A2 (pt) | Método para produção de beta-santaleno | |
| BRPI1008253A2 (pt) | Metoso para tratar biomassa | |
| BRPI0924019A2 (pt) | método de fermentação e aparelhos adaptados para o método | |
| BR112012005763A2 (pt) | método de preparação para materiais bio-combustíveis e produtos bioquímicos | |
| BRPI0906255A2 (pt) | método para produzir leite fermentado | |
| FR2942407B1 (fr) | Procede de photomaquillage et composition de photomaquillage | |
| BR112013016341A2 (pt) | método de congelamento de células |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |